NEW YORK, May 24 (GenomeWeb News) - Genomic Solutions' parent company, Harvard Biosciences, said neither firm is responsible for the erroneous IPO filing attributed to the subsidiary yesterday.
"Contrary to media reports, neither Harvard Bioscience nor its wholly owned subsidiary, Genomic Solutions, yesterday filed a Form S-1 registration statement with the SEC," Harvard Bio said in its statement, which appeared more than one day after multiple news outlets reported that the unit had filed for an initial public offering.
"We believe the source of the error was a service that reports on SEC filings. Generally, we have a policy of not commenting on media reports or rumors, however we have made an exception to correct these erroneous reports," Harvard Bio said.
News services, including GenomeWeb News, yesterday updated their reports to reflect that Genomic Solutions erroneously refiled its initial public offering documents from 2000. It was originally reported that the subsidiary was moving ahead with the $100 million IPO registration. The registration forms were later removed from the SEC's web site.
A Genomic Solutions spokesman told Dow Jones earlier today that the forms it released were an "erroneous reissue." Harvard Bio's statement closes the saga.
Neither Genomic Solutions nor Harvard Bioscience returned GenomeWeb News' calls for comment.